NACFC 2020: Online
October 7 – October 23
Beginning October 7, participants will be able to access posters, network with other NACFC attendees, visit the Supporter Showcase, and watch symposia talks on demand in advance of the live simulcast.
Live sessions – including plenary presentations and symposia discussions – will take place October 21-23.
NACFC brings together scientists, clinicians, and care center staff from around the world to share and discuss the latest advances in cystic fibrosis research, care, and drug development and work towards ways to improve the health and quality of life for people with CF.
For more information visit: www.nacfconference.org
For more information: NACFC@cff.org
The National Institutes of Health has renewed funding for the Dartmouth Cystic Fibrosis (CF) Research Center, one of seven national CF research and translation centers funded by the NIDDK. DartCF, directed by Dean Madden, was launched in 2018. It provides core research facilities, access to clinical samples, biostatistical support, and pilot project funding for groups working on the GI and systemic aspects of CF disease. DartCF works closely with the CF Foundation Research Development Program headed by Bruce Stanton, with the CF and M2P2 training grants headed by George O’Toole and Deb Hogan, and with Dartmouth’s CF Cluster faculty, Jim Bliska and Ben Ross. These colleagues also lead key components of DartCF, together with Ali Ashare, Tim Gardner, and Todd MacKenzie. More than 30 faculty members participate campus wide.
Bruce Stanton, Thomas Hampton and Alix Ashare on COVID-19 and Cystic Fibrosis:
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the CFTR gene. Although viral respiratory tract infections are, in general, more severe in patients with CF compared to the general population, a small number of studies indicate that SARS-CoV-2 does not cause a worse infection in CF. This is surprising since comorbidities including preexisting lung disease have been reported to be associated with worse outcomes in SARS-CoV-2 infections. Several recent studies provide insight into why SARS-CoV-2 may not produce more severe outcomes in CF. First, ACE and ACE2, genes that play key roles in SARS-CoV-2 infection have some variants that are predicted to reduce the severity of SARS-CoV-2 infection. Second, mRNA for ACE2 is elevated and the mRNA for TMPRSS2, a serine protease, is decreased in CF airway epithelial cells. Increased ACE2 is predicted to enhance SARS-CoV-2 binding to cells, but would increase conversion of angiotensin II, which is proinflammatory, to angiotensin-1-7, which is anti-inflammatory. Thus, increased ACE2 would reduce inflammation and lung damage due to SARS-CoV-2. Moreover, decreased TMPRSS2 would reduce SARS-CoV-2 entry into airway epithelial cells. Second, many CF patients are treated with azithromycin, which suppresses viral infection and lung inflammation, and inhibits the activity of furin, a serine protease. Finally, the CF lung contains high levels of serine protease inhibitors including ecotin and SERPINB1, which are predicted to reduce the ability of TMPRSS2 to facilitate SARS-CoV-2 entry into airway epithelial cells. Thus, a variety of factors may mitigate the severity of SARS-CoV-2 in CF.
Read the full article here: https://pubmed.ncbi.nlm.nih.gov/32668165/
Kudos to Dr. Bruce Stanton and his team!
Koeppen K, Hampton TH, Jarek M, Scharfe M, Gerber SA, Mielcarz DW, Demers EG, Dolben EL, Hammond JH, Hogan DA, Stanton BA. A Novel Mechanism of Host-Pathogen Interaction through sRNA in Bacterial Outer Membrane Vesicles. PLoS Pathog. 2016 Jun 13;12(6):e1005672. doi: 10.1371/journal.ppat.1005672. PMID: 27295279; PMCID: PMC4905634.
Sam Neff ’21 published an article in the Fall 2019 issue of Dartmouth Undergraduate Journal of Science, “The Evolution of Cystic Fibrosis Therapy – A Triumph of Modern Medicine.” Click here to access the full text.
Congratulations to Daniel Aridgides, MD, PhD, who has been awarded the LeRoy Matthews Physician-Scientist Award of the Cystic Fibrosis Foundation (CFF) for his research project, “Pseudomonas quorum sensing mutants inhibit alveolar macrophage function.” Dr. Aridgides, a member of Dr. Alix Ashare’s lab, is a Pulmonary/Critical Care Fellow at Dartmouth-Hitchcock. The LeRoy Matthews Physician-Scientist Award provides up to six years of support for outstanding, newly trained pediatricians and internists (M.D.s and M.D./Ph.D.s) to complete sub-specialty training, develop into independent investigators, and initiate a research program.
June 2, 2-3pm EST
See here for the full announcement.
The Cystic Fibrosis Foundation recognizes that the COVID-19 pandemic has had a dramatic impact on the research you conduct, and we want to reassure you that we are committed to providing the necessary support and flexibility to ensure this important work continues.
Join us for a virtual forum to get updates on the issues facing CF investigators during the COVID-19 pandemic. We will discuss key items of interest to the research community including:
- How the pandemic has broadly impacted CF research (e.g. lab closures, workforce impacts)
- The impact of the pandemic on research progress and how that affects CF Foundation progress reports and new grant applications
- Opportunities for supplemental funding and re-budgeting
- The impact of the pandemic on current and future research priorities of the CFF
Attendees are encouraged to submit questions to Ericka Carter (firstname.lastname@example.org) in advance of the Town Hall. Questions may also be submitted live through the Q&A feature of the BlueJeans platform. The Town Hall will be recorded for those who cannot attend live and will be posted on https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/.
To join the Town Hall, select from the following options:
1) Web Browser
2) Joining via a mobile device?
a) Open this link: https://primetime.bluejeans.com/a2m/live-event/vfzrawry
b) Download the app if you don’t have it already.
c) Enter event ID: vfzrawry
Dial one of the following numbers, enter the participant PIN followed by # to confirm:
+1 (415) 466-7000 (US) PIN 2014051 #
+1 (800) 520-9950 (US Toll Free)
+1 (760) 699-0393 (US) PIN 3602850753 #
+1 (877) 305-0280 (US Toll Free)